British Thoracic Society Winter Meeting
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models. -
Glaxosmithkline Bangladesh Limited (GSK)
GlaxoSmithKline Bangladesh Limited (GSK) Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation nd Date of Submission: 2 September, 2014 ©Daffodil International University DAFFODIL INTERNATIONAL UNIVERSITY Internship Report On Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation Submitted To Dr. Zakir Hossain Dean& Professor Faculty of Business & Economics Daffodil International University Submitted By Ishrat Jahan ID: 131-14-1019 Masters of Business Administration Daffodil International University Date of Submission: 2nd September, 2014 ©Daffodil International University Letter of Transmittal September 2, 2014 To Dr. Zakir Hossain Dean & Professor Faculty of Business and Economics Daffodil International University Dhaka-1205 Subject: Submission of internship report on recruitment and selection process: An evaluation of GlaxoSmithKline Bangladesh Limited Sir, I am highly satisfied to submit my report on recruitment and selection process: an evaluation of GSK. For preparing this report I tried my best to accumulate relevant and upgraded information from available sources. In preparing this report, I tried my level best to make it a complete one and sincerely look forward to any possible correction. I am very glad because you also given the opportunity to prepare this report .I hope that this report will meet the standards of your judgments. Your Sincerely ---------------- Ishrat Jahan ©Daffodil International University i Certificate of the Supervisor This is to certify that the internship report titled ―Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation‖, has been prepared by Ms. Ishrat Jahan bearing ID: 131-14-1019 under my supervision, a practical study on GlaxoSmithKline Bangladesh Limited. I think on the basic of declaration Ms. -
SIGN158 British Guideline on the Management of Asthma
SIGN158 British guideline on the management of asthma A national clinical guideline First published 2003 Revised edition published July 2019 Key to evidence statements and recommendations Levels of evidence 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2– Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion Grades of recommendation Note: The grade of recommendation relates to the strength of the supporting evidence on which the evidence is based. It does not reflect the clinical importance of the recommendation. A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results B A body of evidence including studies rated -
EMJ-5.2-2020-4.Pdf
Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al. -
Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation
CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984). -
Wellcome Four Year Phd Programme in Integrative Cell Mechanisms
2021 Wellcome Four Year PhD Programme in Integrative Cell Mechanisms Training the next generation of Molecular Cell Biologists Background and Aims of Programme The Wellcome Four Year PhD Programme in Integrative Cell Mechanisms (iCM) is closely associated with the Wellcome Centre for Cell Biology and trains the next generation of cell and molecular biologists in the application of quantitative methods to understand the inner workings of distinct cell types in different settings. A detailed understanding of normal cellular function is required to investigate the molecular cause of disease and design future treatments. However, data generated by biological research requires increasingly complex analysis with technological advances in sequencing, mass spectrometry/proteomics, super-resolution microscopy, Wellcome Centre for Cell Biology 2021 synthetic and structural biology generating increasingly large, complex datasets. In addition, innovations in computer sciences and informatics are transforming data acquisition and analysis and breakthroughs in physics, chemistry and engineering allow the development of devices, molecules and instruments that drive the biological data revolution. Exploiting technological advances to transform our understanding of cellular mechanisms will require scientists who have been trained across the distinct disciplines of natural sciences, engineering, informatics and mathematics. To address this training need, iCM PhD projects are cross-disciplinary involving two primary supervisors with complementary expertise. Supervisor partnerships pair quantitative scientists with cell biologists ensuring that students develop pioneering cross-disciplinary collaborative projects to uncover cellular mechanisms relevant to health and disease. We aim to recruit students with a variety of backgrounds across the biological and physical sciences, including Biochemistry, Biomedical Science, Cell Biology, Chemistry, Computational Data Sciences, Engineering, Genetics, Mathematics, Molecular Biology and Physics. -
A Professional Development Framework for Paediatric Respiratory Nursing
A professional development framework for paediatric respiratory nursing ISSN 2040-2023: British Thoracic Society Reports Vol 12, Issue 2, May 2021 1 ACKNOWLEDGEMENTS: We are grateful to colleagues at the National Paediatric Respiratory and Allergy Nurses Group (NPRANG) for their support with the development of this document. In particular: Ann McMurray Asthma Nurse Specialist, Royal Hospital for Children and Young People, Edinburgh. NPRANG Chair Bethan Almeida Clinical Nurse Specialist for Paediatric Asthma and Allergy, Imperial College Healthcare NHS Trust Tricia McGinnity Paediatric Cystic Fibrosis Nurse Specialist, Southampton Children's Hospital Emma Bushell Paediatric Respiratory Nurse Specialist – Asthma, Frimley Health NHS Foundation Trust This document has been adapted from the following publication: British Thoracic Society, A professional development framework for respiratory nursing (1). The authors of this original document are: Samantha Prigmore, Co-chair Consultant respiratory nurse, St Georges University Hospitals NHS Foundation Trust Helen Morris, Co-chair ILD nurse specialist, Wythenshawe Hospital Alison Armstrong Nurse consultant (assisted ventilation), Royal Victoria Infirmary Susan Hope Respiratory nurse specialist, Royal Stoke University Hospital Karen Heslop-Marshall Nurse consultant, Royal Victoria Infirmary Jacqui Pollington Respiratory nurse consultant, Rotherham NHS Foundation Trust CONTENTS: Introduction Method of production How to use this document Competency table (Band 5, 6, 7 and 8) Supporting evidence Acknowledgements Declarations of Interest References Content from this document may be reproduced with permission from BTS as long as you conform to the following conditions: • The text must not be altered in any way. • The correct acknowledgement must be included. 2 Introduction Paediatric respiratory nurses are an important component of the multi-professional team for a wide variety of respiratory conditions, providing holistic care for patients in a variety of settings. -
Annual Report 2013
Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD. -
17Th & 18Th June 2021 Speakers' Details and Presentation Summaries
th th SUMMER MEETING ONLINE – 17 & 18 June 2021 Speakers’ Details and Presentation Summaries The following details are in programme order. Use the PDF search button to quickly find a session or speaker. OPEN SESSION – NATIONAL ASTHMA AND COPD AUDIT PROGRAMME Thursday 17th June: 08:00-09:00 Dr James Calvert qualified in Medicine from Oxford Session aims and overview University in 1992. He studied Public Health as a 1) To summarise the main findings of the 2020/21 Fulbright Scholar at Harvard University before NACAP reports. completing his PhD in Asthma Epidemiology in South 2) To outline the QI support opportunities offered by Africa and London. NACAP to clinical and audit teams. He was a Consultant Respiratory Specialist in Bristol from 2006-2021. He is now a Respiratory Consultant Professor Roberts will present a summary of key and Medical Director of Aneurin Bevan University reported findings from across the audits from the last Health Board in Wales. 12 months, highlighting areas for further James has worked with colleagues in the South West improvement. He will speak about the impact of and at NHS England to improve access to integrated COVID-19 on standards of care and on audit services for respiratory patients. He has Chaired the participation, along with plans to improve automated British Thoracic Society (BTS) Professional and extraction of NACAP data. Organisational Standards Committee and has been Dr Calvert will talk about the QI programme to be the BTS National Audit Lead. He has a longstanding launched this year. interest in quality improvement in health care and has A discussion will follow around ideas for improving worked with the BTS, NHS Improving Value, the Royal NACAP support to clinical and audit teams. -
A Bibliometric Analysis
787 Original Article Page 1 of 9 The 100 most cited articles on lung cancer screening: a bibliometric analysis Meng Li1,2, Qiang Cai2,3, Jing-Wen Ma1, Li Zhang1,2, Claudia I. Henschke2 1Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Radiology, Mount Sinai Health System, New York, NY, USA; 3Department of Radiology, Shanxi Provincial People’s Hospital, Taiyuan, China Contributions: (I) Conception and design: M Li, CI Henschke; (II) Administrative support: CI Henschke; (III) Provision of study materials or patients: M Li, CI Henschke; (IV) Collection and assembly of data: M Li, L Zhang; (V) Data analysis and interpretation: M Li, Q Cai, JW Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Claudia I. Henschke. Department of Radiology, Mount Sinai Health System, 1 Gustave Levy Place, New York, NY 10029, USA. Email: [email protected]. Background: The number of citations of an article reflects its impact on the scientific community. The aim of this study was to identify and characterize the 100 most cited articles on lung cancer screening. Methods: The 100 most cited articles on lung cancer screening published in all scientific journals were identified using the Web of Science database. Relevant data, including the number of citations, publication year, publishing journal and impact factor (IF), authorship and country of origin, article type and study design, screening modality, and main topic, were collected and analyzed. Results: The 100 most cited articles were all English and published between 1973 and 2017, with 81 published after 2000. -
A Case Study of Glaxosmithkline Plc )
)l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal. -
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.